Jae H Park

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells
    Jae H Park
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Discov Med 9:277-88. 2010
  2. doi request reprint Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?
    Jae H Park
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Expert Rev Hematol 4:427-36. 2011
  3. pmc Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
    Jae H Park
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 118:1248-54. 2011
  4. doi request reprint ATRA plus arsenic gets another "A" in APL
    Jae H Park
    Memorial Sloan Kettering Cancer Center, USA
    Blood 120:1535-6. 2012
  5. doi request reprint Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia
    Dan Douer
    Dan Douer, Matthew A Lunning, Patrick W Burke, Jae H Park, and Martin S Tallman, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY Ibrahim Aldoss, Laleh Ramezani, Lisa Mark, Janice Vrona, Vinod Pullarkat, and Ann M Mohrbacher, Keck School of Medicine, University of Southern California and Vassilios I Avramis, Children s Hospital of Los Angeles, University of Southern California, Los Angeles, CA
    J Clin Oncol 32:905-11. 2014
  6. ncbi request reprint Curing all patients with acute promyelocytic leukemia: are we there yet?
    Muhamed Baljevic
    Department of Medicine, New York Presbyterian Hospital Weill Cornell Medical Center, 525 East 68th Street, Box 130, New York, NY 10065, USA
    Hematol Oncol Clin North Am 25:1215-33, viii. 2011
  7. ncbi request reprint Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
    MARCO L DAVILA
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
    Int J Hematol 99:361-71. 2014
  8. doi request reprint Immunotherapies in CLL
    Jae H Park
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Adv Exp Med Biol 792:241-57. 2013
  9. doi request reprint All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129
    Dan Douer
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
    Leuk Res 37:795-801. 2013
  10. pmc Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 118:4817-28. 2011

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells
    Jae H Park
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Discov Med 9:277-88. 2010
    ....
  2. doi request reprint Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?
    Jae H Park
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Expert Rev Hematol 4:427-36. 2011
    ..Cure rates of APL can be further increased by implementing management strategies to reduce early hemorrhagic deaths, which remain the major cause of treatment failure with the current therapy...
  3. pmc Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
    Jae H Park
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 118:1248-54. 2011
    ..These data highlight a need to educate health care providers across a wide range of medical fields, who may be the first to evaluate patients with APL, to have a major effect on early death and the cure rate of APL...
  4. doi request reprint ATRA plus arsenic gets another "A" in APL
    Jae H Park
    Memorial Sloan Kettering Cancer Center, USA
    Blood 120:1535-6. 2012
    ....
  5. doi request reprint Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia
    Dan Douer
    Dan Douer, Matthew A Lunning, Patrick W Burke, Jae H Park, and Martin S Tallman, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY Ibrahim Aldoss, Laleh Ramezani, Lisa Mark, Janice Vrona, Vinod Pullarkat, and Ann M Mohrbacher, Keck School of Medicine, University of Southern California and Vassilios I Avramis, Children s Hospital of Los Angeles, University of Southern California, Los Angeles, CA
    J Clin Oncol 32:905-11. 2014
    ..We studied a pegaspargase dosing strategy based on its pharmacokinetic characteristics in adults...
  6. ncbi request reprint Curing all patients with acute promyelocytic leukemia: are we there yet?
    Muhamed Baljevic
    Department of Medicine, New York Presbyterian Hospital Weill Cornell Medical Center, 525 East 68th Street, Box 130, New York, NY 10065, USA
    Hematol Oncol Clin North Am 25:1215-33, viii. 2011
    ....
  7. ncbi request reprint Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
    MARCO L DAVILA
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
    Int J Hematol 99:361-71. 2014
    ..We highlight the potential risks and benefits by targeting these poor outcome hematologic malignancies. ..
  8. doi request reprint Immunotherapies in CLL
    Jae H Park
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Adv Exp Med Biol 792:241-57. 2013
    ..Among the most novel and promising of these approaches are chimeric antigen receptor (CAR)-based cell therapies that combine advances in genetic engineering and adoptive immunotherapy. ..
  9. doi request reprint All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129
    Dan Douer
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
    Leuk Res 37:795-801. 2013
    ..Nine (4.6%) relapsed late (>3 years from CR), the last occurred after 4.6 years; 7 of them were still alive after 5.5-15 years. In APL patients, late relapses are uncommon, and those who sustain CR >5 years can be considered cured...
  10. pmc Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
    Renier J Brentjens
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 118:4817-28. 2011
    ..These studies are registered at www.clinicaltrials.org as #NCT00466531 (CLL protocol) and #NCT01044069 (B-ALL protocol)...
  11. ncbi request reprint Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy
    Jae H Park
    Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA
    Oncology (Williston Park) 25:733-41. 2011
    ..Cure rates of APL may be further increased by adopting management strategies to reduce early hemorrhagic deaths, which now appear to be the major cause of treatment failure...
  12. pmc Cellular therapies in acute lymphoblastic leukemia
    Jae H Park
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 569, New York, NY 10065, USA
    Hematol Oncol Clin North Am 25:1281-301. 2011
    ....